As Seen on the Show

FDA Approves New Treatment For Wet AMD, Leading Cause of Vision Loss


It’s estimated that 1.75 million people in the US are living with the most severe type of the disease, called wet age-related macular degeneration, or wet AMD.

Age-related macular degeneration is a leading cause of vision loss, and is a growing health concern.

Patients with wet AMD typically experience distorted vision, making it difficult to see objects clearly. If allowed to progress, wet AMD can lead to loss of central vision, leaving patients unable to perform basic activities. The disease typically affects patients 60 years and older, but can occur earlier.

Now, the FDA has approved a new treatment with the potential to help people with wet AMD maintain their vision.

We spoke with Dr. Peter Kaiser, Director of the Cole Center for Ocular Research and Evaluation and Professor of Ophthalmology at the Cleveland Clinic about the impact of wet AMD and a new treatment option available for patients with this disease.

“Wet AMD or Age-related macular degeneration is the number one cause of blindness in people over the age of 60,” said Kaiser. “It’s important patients get treated as soon as possible. If you have decrease in vision, inability to see faces and/or blurred vision, go see your physician immediately.”

“This has a strong genetic component.  Eat healthy, don’t smoke and anything that is good for your body will help prevent the onset of Wet AMD,” said Kaiser. “To know if you have Wet AMD, you should go to your physician and get your eyes checked.”

“The new treatment is called Beovu and this allows patients to be treated only four times a year.  It’s a big change for our patients and will allow them to come in and becomes less of a burden on them.”